[ad_1]
There are growing doubts about the results of the clinical trial and the efficacy of the AstraZeneca Plc and University vaccine after an error in the procedure was identified.
According to Bloomberg, while AstraZeneca and the University of Oxford announced Monday that the results of the final study of its coronavirus vaccine showed it to be 70% effective on average, the few details that have been released have raised concerns about whether the Regulators could authorize its removal.
A statement from the University of Oxford later said that a difference in the production process had led some participants to take half the dose rather than the full one.
AstraZeneca and the University of Oxford said their vaccine was 90% effective when given half a dose before the second full dose, adding that two full doses showed 62% effectiveness.
However, the head of the US vaccine program, known as Operation Warp Speed, said the next day that the dose showing the greatest efficacy was tested in younger populations, adding that half the dose was administered. some participants due to an error in the amount of vaccine. it contained some vials. None of the above was disclosed in AstraZeneca’s original statement.
The findings generated optimism that the end of the pandemic is in sight and that many vaccines to combat the coronavirus could be ready soon, following positive results also announced by Pfizer Inc. and Moderna Inc.
AstraZeneca and the University of Oxford are also close, although the way they handled their large clinical trial has shocked scientists and investors, increasing the risk of slowing their efforts.
In a statement, the University of Oxford said that when it was discovered that a lower dose was being used, it was discussed with regulators and an agreement was reached to promote both regimens. “Concentration measurement methods are already in place and we can ensure that all vaccine batches are now equivalent,” the university said.
An AstraZeneca spokesperson said the tests were carried out “to the highest standards” and that further tests were underway to determine the effectiveness of the vaccine.
“The most likely explanation for divergent efficacy in your mid-term analysis is random or related to patient demographics,” wrote Sam Fazeli, an analyst at Bloomberg Intelligence. “In any case, approval based on current data means that people will be vaccinated with a vaccine whose true effectiveness is unknown.”
Read the news from Greece and the world, with the reliability and validity of News247.gr
[ad_2]
